Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1986 Mar;21(2):93–99. doi: 10.1007/BF00199855

Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives

Saburo Sone 1, Gabriel Lopez-Berestein 2, Isaiah J Fidler 1,✉
PMCID: PMC11038426  PMID: 3081250

Abstract

We investigated whether human peripheral blood monocytes isolated by centrifugal elutriation from healthy donors could be acitivated to become tumoricidal and release tumor cytolytic factor (TCF) subsequent to incubation with recombinant human interferon-gamma (r-IFN-γ) or a derivative of muramyl dipeptide (nor-MDP), or both. Blood monocytes incubated in endotoxin-free medium containing up to 1000 U/ml of r-IFN-γ or in medium containing less than 1 μg/ml of nor MDP were not activated to lyse radiolabeled allogeneic human tumor cells. In contrast, the incubation of monocytes with various dose combinations of r-IFN-γ and nor-MDP generated significant direct cytotoxic activity as well as production of TCF. Preincubation of the r-IFN-γ and nor-MDP mixture with polymyxin B did not inhibit the synergism, thus ruling out the possibility that the process was due to endotoxin contamination. TCF harvested from monocyte culture supernatants was cytolytic against five allogeneic tumor targets, but not against a nontumorigenic cell line. Collectively, the data demonstrate that r-IFN-γ can prime human blood monocytes to allow their activation by synthetic nor-MDP.

Keywords: Polymyxin, Muramyl Dipeptide, Human Peripheral Blood Monocyte, Allogeneic Tumor, Centrifugal Elutriation

Footnotes

On leave from the Department of Internal Medicine, The University of Tokushima School of Medicine, Kuramoto-cho, Tokushima 770, Japan

References

  • 1.Basham TY, Merigan TC. Recombinant interferon-γ increases HLA-DR synthesis and expression. J Immunol. 1983;130:1492. [PubMed] [Google Scholar]
  • 2.Butler T, Smith E, Hammarstrom L, Moller G. Polymyxins as inhibitors of polyclonal B-cell activators in murine lymphocyte cultures. Infect Immun. 1977;16:449. doi: 10.1128/iai.16.2.449-455.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cailleau R, Olive M, Cruciger QVJ. Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization. In Vitro. 1978;14:911. doi: 10.1007/BF02616120. [DOI] [PubMed] [Google Scholar]
  • 4.Cameron DJ. In vitro killing of tumor cells by macrophage factors obtained from cancer patients and normal donors. J Reticuloendothel Soc. 1982;32:247. [PubMed] [Google Scholar]
  • 5.Cameron DJ, Churchill WH. Cytotoxicity of human macrophages for tumor cells: Enhancement by human lymphocyte mediators. J Clin Invest. 1979;63:977. doi: 10.1172/JCI109398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Change ZL, Hoffman T, Bonvini E, Stevenson HC, Herberman RB. Spontaneous cytotoxicity by monocyte-enriched subpopulations of human peripheral blood mononuclear cells against human or mouse anchoragedependent tumor cell lines: Contribution of NK-like cells. Scand J Immunol. 1983;18:439. doi: 10.1111/j.1365-3083.1983.tb00876.x. [DOI] [PubMed] [Google Scholar]
  • 7.Erickson KL, Cicurel L, Gruys E, Fidler IJ. Murine T-cell hybridomas that produce lymphokine with macrophage-activating factor activity as a constitutive product. Cell Immunol. 1982;72:195. doi: 10.1016/0008-8749(82)90297-0. [DOI] [PubMed] [Google Scholar]
  • 8.Fidler IJ, Kleinerman ES. Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol. 1984;2(8):937. doi: 10.1200/JCO.1984.2.8.937. [DOI] [PubMed] [Google Scholar]
  • 9.Fidler IJ, Poste G. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Semin Immunopathol. 1982;5:161. doi: 10.1007/BF00199794. [DOI] [PubMed] [Google Scholar]
  • 10.Fidler IJ, Schroit AJ. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: In situ activation of macrophages and therapy of spontaneous cancer metastases. J Immunol. 1984;133(1):515. [PubMed] [Google Scholar]
  • 11.Gray PW, Leung DW, Pennica D, et al. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature. 1982;295:503. doi: 10.1038/295503a0. [DOI] [PubMed] [Google Scholar]
  • 12.Guyre PM, Morganelli PM, Miller R. Recombinant immune interferon increases immunoglubulin G Fc receptors on cultured human mononuclear phagocytes. J Clin Invest. 1983;72:393. doi: 10.1172/JCI110980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Hammerstrom J. Soluble cytostatic factor(s) released from human macrophages. Scand J Immunol. 1982;15:311. doi: 10.1111/j.1365-3083.1982.tb00654.x. [DOI] [PubMed] [Google Scholar]
  • 14.Herberman RB, Ortaldo JR, Rubinstein M, Pestka S. Augmentation of natural and antibody-dependent cell-mediated cytotoxicity by pure human leukocyte interferon. J Clin Immunol. 1981;1:149. doi: 10.1007/BF00922756. [DOI] [PubMed] [Google Scholar]
  • 15.Hester JR, Kellogg RM, Mulzet AP, Kruger VR, McCredie KB, Freireich EJ. Principles of blood separation and component extraction in a disposable continous-flow single-stage channel. Blood. 1979;54:254. [PubMed] [Google Scholar]
  • 16.Horwitz DA, Linker-Israeli M, Bakke AC, Nishiya K. Interferon enhances NK cell activity but not spontaneous cytotoxicity by monocytes. Fed Proc. 1983;42:5424. [Google Scholar]
  • 17.Horwitz DA, Bakke AC, Abo W, Nishiya K. Monocyte and NK cell cytotoxic activity in human adherent cell preparations: Discriminating effects of interferon and lactoferrin. J Immunol. 1984;132:2370. [PubMed] [Google Scholar]
  • 18.Kleinerman ES, Herberman RB. Tumoricidal activity of human monocytes: Evidence for cytolytic function distinct from that of NK cells. J Immunol. 1984;133:4. [PubMed] [Google Scholar]
  • 19.Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Research. 1983;43:2010. [PubMed] [Google Scholar]
  • 20.Kleinerman ES, Schroit AJ, Fogler WE, Fidler IJ. Tumoricidal activity of human monocytes activated in vitro by free liposome-encapsulated human lymphokines. J Clin Invest. 1983;72:304. doi: 10.1172/JCI110970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Kleinerman ES, Zicht R, Sarin PS, Gallo RC, Fidler IJ. Constitutive production and release of a lymphokine with macrophage-activating factor activity distinct from gamma-interferon by a human T-cell leukemia virus-positive cell line. Cancer Research. 1984;44:4470. [PubMed] [Google Scholar]
  • 22.Kleinschmidt WJ, Schultz RM. Similarities of murine gamma interferon and the lymphokine that renders macrophages cytotoxic. J Interferon Res. 1982;2:291. doi: 10.1089/jir.1982.2.291. [DOI] [PubMed] [Google Scholar]
  • 23.Koff WC, Fidler IJ, Showalter SD, Chakrabarty MK, Hampar B, Ceccorulli LM, Kleinerman ES. Human monocytes activated by immunomodulators in liposomes lyse herpes virus infected but not normal cells. Science. 1984;224:1007. doi: 10.1126/science.6426057. [DOI] [PubMed] [Google Scholar]
  • 24.Koff WC, Fogler WE, Gutterman J, Fidler IJ (1985) Efficient activation of human blood monocytes to a tumoricidal state by liposomes containing human recombinant gamma interferon. Cancer Immunol Immunother in press [DOI] [PMC free article] [PubMed]
  • 25.Le J, Prensky W, Yip YK, Chang Z, Hoffman T, Stevenson HC, Balazs I, Sadlik JR, Vilcek J. Activation of human monocyte cytotoxicity by natural and recombinant immune interferon. J Immunol. 1983;131:2821. [PubMed] [Google Scholar]
  • 26.Lopez-Berestein G, Mehta K, Mehta R, Juliano RL, Hersh EM. The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J Immunol. 1983;130:1500. [PubMed] [Google Scholar]
  • 27.Mannel DN, Falk W. Interferon-γ is required in activation of macrophages for tumor cytotoxicity. Cell Immunol. 1983;79:396. doi: 10.1016/0008-8749(83)90082-5. [DOI] [PubMed] [Google Scholar]
  • 28.Mantovani A, Dean JH, Jerrells TR, Herberman RB. Augmentation of tumoricidal activity of human monocytes and macrophages by lymphokines. Int J Cancer. 1980;25:691. doi: 10.1002/ijc.2910250602. [DOI] [PubMed] [Google Scholar]
  • 29.Matthews N. Production of an anti-tumor cytotoxin by human monocytes. Immunology. 1981;44:135. [PMC free article] [PubMed] [Google Scholar]
  • 30.Meltzer MS, Benjamin WR, Farrar JJ. Macrophage activation for tumor cytotoxicity: Induction of macrophage tumoricidal activity by lymphokines from EL-4, a continuous T-cell line. J Immunol. 1982;129:2802. [PubMed] [Google Scholar]
  • 31.Morrison DC, Jacob DM. Binding of polymyxin B to the lipid. A portion of bacterial lipopolysaccharides. Immunochemistry. 1976;13:813. doi: 10.1016/0019-2791(76)90181-6. [DOI] [PubMed] [Google Scholar]
  • 32.Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-γ as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983;158:670. doi: 10.1084/jem.158.3.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Nacy CA, James SL, Benjamin WR, Farrer JJ, Hockmeyer WT, Meltzer MS. Activation of macrophages for microbicidal and tumoricidal effector functions by soluble factors from EL-4, a continuous T cell line. Infect Immun. 1983;40:820. doi: 10.1128/iai.40.2.820-824.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Nissen-Meyer J, Hammerstrom J. Physicochemical characterization of cytostatic factors released from human monocytes. Infect Immun. 1982;38:67. doi: 10.1128/iai.38.1.67-73.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Pace JL, Russell SW, Schreiber RD, Altman A, Katz DH. Macrophage activation: Priming activity from a T-cell hybridoma is attributable to interferon-γ. Proc Natl Acad Sci USA. 1983;80:3782. doi: 10.1073/pnas.80.12.3782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Pace JL, Russell SW, Torres BA, Johnson HM, Gray PW. Recombinant mouse r-interferon induces the priming step in macrophages activation for tumor cell killing. J Immunol. 1983;130:2011. [PubMed] [Google Scholar]
  • 37.Ratliff TL, Thomasson DL, McCool RE, Catalona WJ. T-cell hybridoma production of macrophage activation factor (MAF) I. Separation of MAF from interferon gamma. J Reticuloendothel Soc. 1982;31:393. [PubMed] [Google Scholar]
  • 38.Roberts WK, Vasil A. Evidence for the identity of murine macrophage activating factor. J Interferon Res. 1982;2:519. doi: 10.1089/jir.1982.2.519. [DOI] [PubMed] [Google Scholar]
  • 39.Ruco LP, Meltzer MS. Macrophage activation for tumor cytotoxicity: Development of macrophage cytotoxic activity requires completion of a sequence of short-lived intermediary reactions. J Immunol. 1978;121:2035. [PubMed] [Google Scholar]
  • 40.Ruco LP, Meltzer MS. Macrophage activation for tumor cytotoxicity: Tumoricidal activity by macrophages from C3H/HeJ mice requires at least two activation stimuli. Cell Immunol. 1978;41:35. doi: 10.1016/s0008-8749(78)80026-4. [DOI] [PubMed] [Google Scholar]
  • 41.Schultz RM, Kleinschmidt WJ. Functional identy between murine α interferon and macrophage activating factor. Nature. 1983;305:239. doi: 10.1038/305239a0. [DOI] [PubMed] [Google Scholar]
  • 42.Schreiber RD, Pace JL, Russell SW, Altman A, Katz DH. Macrophage activating factor produced by a T-cell hybridoma: Physiochemical and biosynthetic resemblance to γ-interferon. J Immunol. 1983;131:826. [PubMed] [Google Scholar]
  • 43.Sone S, Fidler IJ. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J Immunol. 1980;125:2454. [PubMed] [Google Scholar]
  • 44.Sone S, Tsubura E. Human alveolar macrophages: Potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide. J Immunol. 1982;129:1313. [PubMed] [Google Scholar]
  • 45.Sone S, Poste G, Fidler IJ. Rat alveolar marcophages are susceptible to activation by free and liposome-encapsulated lymphokines. J Immunol. 1980;124:2197. [PubMed] [Google Scholar]
  • 46.Sone S, Moriguchi S, Shimizu E, Ogushi F, Tsubura E. In vitro generation of tumoricidal properties in human alveolar macrophages following interaction with endotoxin. Cancer Res. 1982;42:2227. [PubMed] [Google Scholar]
  • 47.Sone S, Mutsuura S, Ogawara M, Tsubura E. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. J Immunol. 1984;132:2105. [PubMed] [Google Scholar]
  • 48.Sone S, Tachibana K, Ishii K, Ogawara M, Tsubura E. Production of a tumor cytolytic factor(s) by activated human alveolar macrophages and its action. Cancer Res. 1984;44:646. [PubMed] [Google Scholar]
  • 49.Sone S, Lopez-Berestein G, Fidler IJ (1985) The kinetics and function of tumor cytotoxic factor(s) produced by human blood monocytes activated to the tumoricidal state, J Natt Cancer Inst in press [PubMed]
  • 50.Svedersky LP, Benton CV, Berger WH, Rinderknecht E, Harkins RN, Palladino MA. Biological and antigenic similatities of murine interferon-γ and macrophage-activating factor. J Exp Med. 1984;159:812. doi: 10.1084/jem.159.3.812. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES